The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease Study [28], a dedicated study on the use of SGLT-2 inhibitors in chronic kidney disease, clearly showed a benefit for the drug in chronic kidney disease. This evidence concerns the gene SLC5A2 and chronic kidney disease.